The PI3K/AKT pathway as a target for cancer treatment

Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journalArticle

273 Scopus citations

Abstract

Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

Original languageEnglish (US)
Pages (from-to)11-28
Number of pages18
JournalAnnual Review of Medicine
Volume67
DOIs
Publication statusPublished - Jan 14 2016

    Fingerprint

Keywords

  • Breast cancer
  • Lymphoproliferative disorders
  • Mammalian target of rapamycin (mTOR)
  • Mutation
  • Pathway inhibitors
  • Phosphoinositide 3-kinase (PI3K)/AKT

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this